Cargando…

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

This case describes typical ophthalmic findings as a key feature for diagnosis of progressive multifocal leukoencephalopathy (PML) and its possible differential diagnosis. A 58-year-old female patient with relapsing-remitting multiple sclerosis on immunotherapy with natalizumab developed visual dist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herold, Tina Rike, Jakl, Veronika, Graser, Anno, Eibl-Lindner, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413346/ https://www.ncbi.nlm.nih.gov/pubmed/22888211 http://dx.doi.org/10.2147/OPTH.S30636

Ejemplares similares

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Natalizumab-associated Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis: A Mini Review
por: Fayyaz, Muniba, et al.
Publicado: (2018)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
por: Vivekanandan, Govinathan, et al.
Publicado: (2021)

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
por: Dong-Si, Tuan, et al.
Publicado: (2015)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis
por: Manenti, Guglielmo, et al.
Publicado: (2013)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Presymptomatic Diagnosis with MRI and Adequate Treatment Ameliorate the Outcome after Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Lindå, Hans, et al.
Publicado: (2013)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
por: Küpper, Clemens, et al.
Publicado: (2019)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report
por: De Masi, Roberto, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy
por: Adang, Laura, et al.
Publicado: (2015)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
por: Mansoor, Salman, et al.
Publicado: (2021)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Treatment of progressive multifocal leukoencephalopathy
por: Castle, Daniel, et al.
Publicado: (2019)

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
por: De Mercanti, Stefania Federica, et al.
Publicado: (2020)

Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study
por: Pontillo, Giuseppe, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient?
por: Johansen, Krisztina K., et al.
Publicado: (2013)

Progressive multifocal leukoencephalopathy in an immunocompetent patient
por: van der Kolk, Nicolien M., et al.
Publicado: (2016)

Diagnostic delay in progressive multifocal leukoencephalopathy
por: Miskin, Dhanashri P., et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy in the absence of immunosuppression
por: Zucker, Benjamin E., et al.
Publicado: (2017)

Progressive Multifocal Leukoencephalopathy: Current Insights
por: Kartau, Marge, et al.
Publicado: (2019)

AIDS-related progressive multifocal leukoencephalopathy
por: Abrão, Carolina de Oliveira, et al.
Publicado: (2020)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Advances in Treatment of Progressive Multifocal Leukoencephalopathy
por: Bernard‐Valnet, Raphaël, et al.
Publicado: (2021)

Hemianopia
por: Hartridge, Gustavus
Publicado: (1898)

CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m6d3u037e9qh6sqn59l8at9b8u